Actively Recruiting
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
Led by Institute of Oncology Ljubljana · Updated on 2021-09-23
62
Participants Needed
1
Research Sites
340 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to identify the most promising sequence of modalities in total neoadjuvant treatment of localy advanced rectal cancer with high risk of recurrence
CONDITIONS
Official Title
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed rectal adenocarcinoma
- No distant metastases on CT scan (M0 disease)
- At least one high-risk factor for recurrence on MRI, including T4 tumor (cT4), N2 disease (cN2), extramural venous invasion (cEMVI+), positive lateral lymph nodes, or tumor/lymph nodes 1 mm or less from mesorectal fascia (cMRF+)
- Ability to provide informed consent
- Willingness to attend regular check-ups during and after treatment
You will not qualify if you...
- History of previous radiation therapy in the pelvic area
- Absolute contraindications for MRI
- Distant metastases cannot be reliably excluded
- Presence of synchronous cancer
- Chronic inflammatory bowel disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Oncology
Ljubljana, Slovenia, 1000
Actively Recruiting
Research Team
V
Vaneja Velenik, PhD
CONTACT
M
Miha Orazem, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here